Navigation Links
New hope for heart failure patients
Date:9/1/2009

MAYWOOD, Il -- A therapy called cardiac resynchronization can significantly delay the progression of heart failure, according to a major international study published in the New England Journal of Medicine.

The treatment reduced the risk of serious heart failure events by 41 percent, the study found. "This shows, for the first time, that the onset of heart failure symptoms and hospitalization for heart failure can be delayed with pacing therapy," said Dr. David Wilber, a co-author of the study and director of the Cardiovascular Institute at Loyola University Chicago Stritch School of Medicine.

A device implanted in the upper chest delivers electrical impulses that help synchronize contractions of the left ventricle, the heart's main pumping chamber.

The study included 1,820 patients from 110 centers in the United States, Canada and Europe. Loyola enrolled 13 patients. All patients in the trial had been diagnosed with early stage, mild heart failure (Class 1 and Class 2 on the New York Heart Association classification system). The study's principle investigator is Dr. Arthur Moss of the University of Rochester Medical Center.

Patients were randomly assigned to two groups. A control group received an implanted defibrillator, and a second group received a defibrillator plus cardiac resychronization. (A defibrillator is a device that shocks the heart back to a normal rhythm if the patient experiences a life-threatening irregular heartbeat.)

Compared with the control group, the cardiac resychronization group had a significantly improved heart-pumping efficiency and a 41 percent lower risk of heart-failure events that required hospitalization or outpatient treatment with intravenous drugs.

Loyola heart failure patient Rosemary Jakubowski of Elmwood Park, Il. said that before she received cardiac resychronization, she had experienced significant fatigue. "I always had that dragging feeling," she said.

Since receiving cardiac resychronization, Jakubowski has been taking kickboxing and swim aerobics classes, without fatigue. "I'm 100 percent better -- complete satisfaction," she said. "It's like I'm a new person."

The Food and Drug Administration has approved cardiac resychronization for patients with Class 3 (moderate) and Class 4 (severe) heart failure. Such patients experience marked limitations in physical activity or are unable to do any physical activity at all without discomfort.

"With this study, we have shown that certain patients with early-stage, mild heart failure also can benefit from cardiac resychronization," Wilber said.

The study was presented at the European Society of Cardiology Congress in Barcelona. It was supported by a research grant from Boston Scientific, which makes a cardiac resychronization device. Wilber has received lecture fees and grant support from Boston Scientific.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Oldest Heart Patients May Get Most From Warfarin
2. This Guys Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations
3. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
4. Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients
5. ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity
6. Newer, Better Tests for Heart Attacks
7. Hormone therapy for prostate cancer patients with heart conditions linked to increased death risk
8. Women More Prone to Die in Month After Heart Attack
9. American Beverage Association Response to American Heart Association Statement on Added Sugars
10. Testosterone Therapy May Help Men With Heart Failure
11. Why thick blood protects from a heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... “Fred Rides a Train” allows readers to tag along on a special shopping trip ... the creation of published author, Janet Morrison, who has been writing mostly poetry, essays, ... Dog" series is her first attempt at writing for children. Janet, Fred, and two ...
(Date:12/7/2016)... ... 2016 , ... The Business Architecture Guild is ... on March 21-22, 2017. This premier event features business practitioners and experts from ... of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, and utilities. ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home care ... proud to announce new city-specific pages as part of its ambitious website relaunch. As ... often look, first, for local agencies serving their city. The new site has several ...
(Date:12/6/2016)... ... December 06, 2016 , ... People with ... be seen on a type of MRI, according to a study appearing online ... the central nervous system characterized by tremors or trembling and stiffness in the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a higher risk of serious health problems, such as cardiovascular illness, according ... Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... Dec. 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... targeted kinase medicines for patients with genomically defined diseases, ... offering of $125,000,000 million in shares of its common ... underwriters a 30-day option to purchase up to an ... stock in connection with the public offering. All shares ...
Breaking Medicine Technology: